Pfizer Inc(PFE-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low24.13
Day High24.57
Open:24.15
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Quiver Quantitative, Inc.
Trump’s Newly Disclosed Moderna Trades Preceded FDA Advisory Panel’s Unanimous Backing of mRNA Flu Vaccine
Motley Fool
Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant
Tipranks
Pfizer Expands Migraine Strategy With New Rimegepant Redosing Study
Motley Fool
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
StockStory
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down
LKQ
Tipranks
Pfizer’s Real‑World COVID-19 Vaccine Study Nears Data Reveal: What Investors Should Watch
Motley Fool
Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?
Zacks Investment Research
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Motley Fool
The Fine Print Most Canadians Miss When Holding U.S. Stocks in a TFSA
Motley Fool
Why Pfizer Could Prove to Be an Underrated GLP-1 Stock
Motley Fool
Big Pharma Has a Case of Merger Mania
Motley Fool
Nike Just Hit an 11-Year Low. Will Its Turnaround Finally Start on Wednesday?
Motley Fool
3 No-Brainer Dividend Stocks to Buy Right Now
Newswire.ca
Perioperative Option Approved in Canada for Patients with Muscle-Invasive Bladder Cancer Unable to Receive Cisplatin-Based Therapy
Motley Fool
3 Monster Stocks to Buy Right Now With Dividend Yields of 5% or More
Motley Fool
A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?
Motley Fool
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
Motley Fool
The Market Just Pulled Back Again. These 3 Blue Chips Are the Ones to Buy.
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Unicycive Therapeutics (UNCY)

Profile

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.'The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.